Overexpression of epithelial growth factor receptor (EGFR) predicts better response to neo-adjuvant chemotherapy in patients with triple-negative breast cancer

Yi-qing, Tang; Zhu, Li; Li, Yafen; Ji, Jun; Li, Jianfang; Yuan, Fei; Wang, Dengbin; Chen, Weiguo; Huang, Ou; Chen, Xiaosong; Wu, Jiayi; Shen, Kunwei; Loo, Wings T.Y.; Chow, Louis W.C.

doi:10.1186/1479-5876-10-s1-s4

Cited by 26 publications

(25 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of 480 studies were first identified for evaluation. Based on the criteria described in the methods, 19 publications were eligible for inclusion in the present meta-analysis (10,12,(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31). The bibliographies of these 19 publications were also searched, but this did not provide further studies for inclusion.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Effect of neoadjuvant chemotherapy in patients with triple-negative breast cancer: A meta-analysis

Tian

Zhou

et al. 2015

Oncology Letters

View full text Add to dashboard Cite

Abstract. The present meta-analysis aimed to evaluate the effect of neoadjuvant chemotherapy on pathological complete response (pCR) and survival rate in patients with triple-negative breast cancer (TNBC). Specific inclusion and exclusion criteria were used to conduct a search of the available databases, in order to find studies performed between January 2006 and January 2014. The bibliographies of the included studies were examined with the same criteria. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group framework was used to evaluate the included studies, and RevMan 5.1 and GRADEprofiler 3.6 were used to analyze the extracted data. A total of 19 studies with 6,180 patients were included. The meta-analysis revealed that the pCR rates in patients with TNBC were significantly higher than those in patients with non-TNBC. The 5-year disease-free survival (DFS) and overall survival (OS) rates were significantly lower in the patients with TNBC compared with those with non-TNBC. Furthermore, these survival rates were significantly higher in the patients with TNBC who achieved a pCR compared with those in the patients who did not achieve a pCR. pCR rates were higher among the patients with TNBC with high Ki-67 expression than among those with low Ki-67 expression. The patients with TNBC exhibited lower survival rates compared with those with non-TNBC, but achieved higher pCR rates. Moreover, those patients achieving a pCR exhibited improved 5-year survival rates, suggesting that the pCR rate could be predictive of survival in patients with TNBC. In addition, high Ki-67 expression may predict the likelihood of a pCR. However, future multicenter randomized controlled trials are required to enhance the quantity and quality of the clinical evidence.

show abstract

Section: Resultsmentioning

confidence: 99%

“…A total of 13 stu dies (10,(15)(16)(17)(18)(19)(20)24,25,(27)(28)(29)(30) reported the pCR rates in patients with TNBC and non-TNBC who received NAC. There was no heterogeneity between the results of different studies (I 2 =23%, P=0.21), so the fixed-effects model was applied for data analysis.…”

Section: Resultsmentioning

confidence: 99%

Effect of neoadjuvant chemotherapy in patients with triple-negative breast cancer: A meta-analysis

Tian

Zhou

et al. 2015

Oncology Letters

View full text Add to dashboard Cite

show abstract

“…Viale et al recently found the EGFR protein expression score to be a prognostic factor among TNBC supporting EGFRtargeted therapy to be clinically relevant [24]. Tang et al reported that TNBC cases with EGFR overexpression have increased pathologic complete response rates to neoadjuvant chemotherapy when compared with non-TNBC cases [25]. In patients with metastatic lung and colorectal cancer, EGFR gene copy number is reported to be a superior predictive marker for EGFR-inhibiting treatment compared to EGFR protein expression [9,26].…”

Section: Discussionmentioning

confidence: 97%

Determination of HER2 and p53 Mutations by Sequence Analysis Method and EGFR/Chromosome 7 Gene Status by Fluorescence in Situ Hybridization for the Predilection of Targeted Therapy Modalities in Immunohistochemically Triple Negative Breast Carcinomas in Turkish Population

Pala

Bayol

Keskin

et al. 2015

Pathol. Oncol. Res.

View full text Add to dashboard Cite

Triple negative breast cancer (TNBC), an agressive subtype accounts nearly 15 % of all breast carcinomas. Conventional chemotherapy is the only treatment modality thus new, effective targeted therapy methods have been investigated. Epidermal growth factor receptor (EGFR) inhibitors give hope according to the recent studies results. Also therapeutic agents have been tried against aberrant p53 signal activity as TNBC show high p53 mutation rates. Our aim was to detect the incidence of mutations/amplifications identified in TNBC in our population. Here we used sequence analysis to detect HER2 (exon 18-23), p53 (exon 5-8) mutations; fluorescence in situ hybridization (FISH) method to analyse EGFR/chromosome 7 centromere gene status in 82 immunohistochemically TNBC. Basaloid phenotype was identified in 49 (59.8 %) patients. EGFR amplification was noted in 5 cases (6.1 %). All EGFR amplified cases showed EGFR overexpression by immunohistochemistry (IHC). p53 mutations were identified in 33 (40.2 %) cases. Almost 60 % of the basal like breast cancer cases showed p53 mutation. Only one case showed HER2 mutation (exon 20:g.36830_3). Our results showed that gene amplification is not the unique mechanism in EGFR overexpression. IHC might be used in the decision of anti-EGFR therapy in routine practice. p53 mutation rate was lower than the rates reported in the literature probably due to ethnic differences and low sensitivity of sanger sequences in general mutation screening. We also established the rarity of HER2 mutation in TNBC. In conclusion EGFR and p53 are the major targets in TNBC also for our population.

show abstract

“…There is now a strong evidence of significant interaction between EGFR and other receptor tyrosine kinases, such as c-MET and IGF-1R, and it is possible that such alternative signaling pathways are involved in determining the effect of these targeted therapies [62]. In addition, some studies have shown a significant correlation between EGFR expression and poor OS and DFS [63]. We in this study also confirmed that EGFR was significantly related to poor OS but in case of DFS, there was no correlation.…”

Section: Egfrmentioning

confidence: 97%

A Meta-Analysis of Biomarkers for the Prognosis of Triple-Negative Breast Cancer Patients

Gui

Yang

et al. 2016

Biomark. Med.

View full text Add to dashboard Cite

show abstract

Overexpression of epithelial growth factor receptor (EGFR) predicts better response to neo-adjuvant chemotherapy in patients with triple-negative breast cancer

Cited by 26 publications

References 30 publications

Effect of neoadjuvant chemotherapy in patients with triple-negative breast cancer: A meta-analysis

Effect of neoadjuvant chemotherapy in patients with triple-negative breast cancer: A meta-analysis

Determination of HER2 and p53 Mutations by Sequence Analysis Method and EGFR/Chromosome 7 Gene Status by Fluorescence in Situ Hybridization for the Predilection of Targeted Therapy Modalities in Immunohistochemically Triple Negative Breast Carcinomas in Turkish Population

A Meta-Analysis of Biomarkers for the Prognosis of Triple-Negative Breast Cancer Patients

Contact Info

Product

Resources

About